ROQU Launches COVID-19 Health Passport
Dublin-based ROQU Group is launching the pilot of Health Passport, a digital platform designed to facilitate increased COVID-19 testing for businesses and the public
Dublin-based ROQU Group is launching the pilot of Health Passport, a digital platform designed to facilitate increased COVID-19 testing for businesses and the public
iCAD has launched ProFound AI Risk to provide accurate two-year, breast cancer risk evaluation, based only on a screening mammogram
Owlstone Medical enters collaboration agreement with Actelion to develop breath-based diagnostic test for pulmonary hypertension.
There isn’t any aspect of healthcare that isn’t being transformed by technology. The health-related technologies on display reflected the work that is being done to prevent illness, to deliver more effective treatments, and to reduce the growing cost of healthcare.
908 Devices, a pioneer of analytical devices for chemical and biomolecular analysis, has raised a $17.5 million Series E financing round led by Northpond Ventures.
Sonde Health, which is developing a voice-based diagnostics platform, has secured $16 million in a Series A financing round led by M Ventures, with MP Healthcare Venture Management, Neoteny 4, LP, Canepa Healthcare, and founder PureTech Health
Researchers at the University of Oxford, the University of Westminster and Perspectum Diagnostics have shown that effective assessment of the health of the liver can be done non-invasively using MRI-based imaging.
NextGen Jane, a diagnostics startup focused on reproductive health, has raised a $9 million Series A round led by Material Impact, with the participation of Access Industries, Viking Global Investors, Liminal Ventures, and several angels.
The Global Commission to End the Diagnostic Odyssey for Children has today published recommendations on how to solve the challenge of diagnosing rare diseases. The commission was set up by Takeda, Microsoft, and EURORDIS-Rare Diseases Europe to find solutions to core barriers preventing timely diagnosis for rare diseases.
SOPHiA GENETICS has closed a $77 million funding round led by Generation Investment Management, with participation from Idinvest Partners, alongside existing investors including Balderton Capital and Alychlo.